MediciNova, Inc

(NASDAQ:MNOV)

Latest On MediciNova, Inc (MNOV):

Date/Time Type Description Signal Details
2023-05-01 11:50 ESTNewsMediciNova to get Canadian patent for liver disease drug MN-001N/A
2023-02-08 23:53 ESTNewsMediciNova rises ~9% after hours on Canadian nod to start long COVID-19 treatment trialN/A
2023-01-31 18:05 ESTNewsMediciNova completes enrollment in mid-stage study of drug for alcohol use disorderN/A
2023-01-11 12:27 ESTNewsMediciNova to get Canadian patent linked to potential skin disorder therapyN/A
2023-01-10 11:46 ESTNewsMediciNova to get patent in Brazil for cholesterol lowering therapyN/A
2022-09-15 19:16 ESTNewsMediciNova to get US patent for MN-166 to treat brain cancerN/A
2022-09-14 07:43 ESTNewsMediciNova to get patent in Canada for MN-001/MN-002 covering certain metabolic disordersN/A
2022-08-16 10:59 ESTNewsMediciNova's MN-166 to be part of study to treat Long COVIDN/A
2022-07-22 19:22 ESTNewsMediciNova begins study of parenteral formulation of MN-166N/A
2022-06-30 14:07 ESTNewsMediciNova announces extension of BARDA contract for Ibudilast developmentN/A
2022-06-23 16:39 ESTNewsMediciNova announces MN-001 research alliance with Juntendo UniversityN/A
2022-06-08 22:06 ESTNewsMediciNova meets key goal in mid-stage trial for COVID-19 therapyN/A
2022-04-08 18:13 ESTNewsMediciNova reports secondary analysis of MN-166 for alcohol use disorderN/A
2022-02-01 11:54 ESTNewsMediciNova nabs new patent in Korea for MN-001 for treatment of blood cholesterolN/A
2022-01-31 20:06 ESTNewsMediciNova stock jumps after securing Canadian patent for MN-001/002 for hepatic ballooningN/A
2022-01-27 17:41 ESTNewsMediciNova receives new European patent for ibudilast for alcohol use disorderN/A
2022-01-26 08:18 ESTNewsMediciNova secures new European patent for MN-001 and MN-002 for hepatic ballooningN/A
2021-12-13 23:29 ESTNewsMediciNova gains 13% after securing new U.S. patent for MN-166 and riluzoleN/A
2021-08-31 11:43 ESTNewsMediciNova: The Pain Of A Positive OutlookN/A
2021-08-13 17:29 ESTNewsMediciNova EPS in-lineN/A
2021-07-21 16:05 ESTNewsMediciNova stock climbs 31% on positive MN-166 data in mid-stage alcohol use disorder studyN/A
2021-07-21 16:05 ESTNewsVirpax Pharmaceuticals, Anavex Life Sciences leads healthcare gainers; Aptevo Therapeutics, Intec Pharma among major losersN/A
2021-07-21 16:04 ESTNewsSAFM, WISH, MVIS and MNOV among after-hours moversN/A
2021-07-21 16:01 ESTNewsMediciNova plans mouse study of MN-166 in chlorine gas-induced lung injuryN/A
2021-07-21 15:58 ESTNewsMediciNova secures new U.S. patent for MN-166 in ophthalmic disease; shares up 9%N/A
2021-04-27 00:12 ESTNewsThe MediciNova Riddle: Worth UnravellingN/A
2021-03-12 08:07 ESTAnalyst RatingThe Analyst Target Price has decreased from $18.5 to $17.63.Neutral
2021-03-09 20:21 ESTNewsMediciNova Jumps on BARDA partnership for Ibudilast developmentN/A
2021-03-05 08:12 ESTEarnings EstimateAn EPS average of -$0.09 is estimated for the quarter ending on June 30, 2021.Sell
2021-03-03 10:28 ESTNewsMediciNova pulls plug on development of COVID-19 vaccineN/A
2021-02-22 11:54 ESTEarnings EstimateAn EPS average of -$0.35 is estimated for the 2022 year.Sell
2021-02-22 08:04 ESTFinancialsCompany financials have been released.Neutral
2021-01-22 02:56 ESTNewsMediciNova rallies as 3D Investment Partners report 11.3% stakeN/A
2021-01-19 01:01 ESTNewsMediciNova nabs new Japanese patent for ibudilast + riluzole in neurodegenerative diseaseN/A
2021-01-12 11:17 ESTNewsMediciNova inks $20M securities purchase agreement with 3D Investment PartnersN/A
2021-01-06 16:11 ESTFinancialsCompany financials have been released.Neutral
2020-12-29 19:25 ESTNewsMediciNova nabs new U.S. patent for ibudilast in multiple sclerosisN/A
2020-12-15 15:23 ESTNewsMediciNova selected for the Nasdaq Biotechnology IndexN/A
2020-11-26 20:50 ESTFinancialsCompany financials have been released.Neutral
2020-11-26 04:05 ESTNewsMediciNova's MN-166 can reduce retinal thinning in progressive multiple sclerosisN/A
2020-11-07 16:29 ESTFinancialsCompany financials have been released.Neutral
2020-11-02 04:19 ESTFinancialsCompany financials have been released.Neutral
2020-10-30 13:50 ESTEarnings EstimateAn EPS average of -$0.16 is estimated for the quarter ending on March 31, 2021.Sell
2020-10-23 03:33 ESTNewsMediciNova on go with ibudilast mid-stage study in chemo-induced nerve damageN/A
2020-09-26 13:25 ESTFinancialsCompany financials have been released.Neutral
2020-09-24 19:26 ESTNewsMediciNova's ibudilast shows positive effect in preventing chemo-induced neuropathyN/A
2020-09-24 19:24 ESTNewsMediciNova slumps 23% on ibudilast data in chemo-induced nerve damageN/A
2020-09-23 11:12 ESTNewsIntranasal COVID-19 vaccine data lifts MediciNova, up 28%N/A
2020-09-17 05:31 ESTFinancialsCompany financials have been released.Neutral
2020-09-16 16:58 ESTInsider TradeHideki Nagao has directly disposed of 1,000 shares and currently holds 15,000 shares.Sell

About MediciNova, Inc (MNOV):

MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. The company is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction. Its product pipeline also includes MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic diseases, including nonalcoholic steatohepatitis and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent for treating solid tumor cancers. The company has a collaboration agreement with BioComo and Mie University for joint development of a SARS-CoV-2 vaccine. MediciNova, Inc. was founded in 2000 and is headquartered in La Jolla, California.

MNOV Quotes by TradingView

See Advanced Chart

General

  • Name MediciNova, Inc
  • Symbol MNOV
  • Type Common Stock
  • Exchange NASDAQ
  • Currency USD
  • Country USA
  • SectorHealthcare
  • IndustryBiotechnology
  • Full Time Employees 9
  • Last Split Factor1:10
  • Last Split Date2006-10-31
  • Fiscal Year EndDecember
  • IPO Date2005-02-08
  • Gic SectorHealth Care
  • Gic GroupPharmaceuticals, Biotechnology & Life Sciences
  • Gic IndustryBiotechnology
  • Gic SubIndustryBiotechnology
  • Web URLhttp://medicinova.com
View More

Valuation

  • Price/Book (Most Recent Quarter) 4.08
View More

Financials

  • Most Recent Quarter 2020-12-31
  • Current Year EPS Estimate -$0.39
  • Next Year EPS Estimate -$0.55
  • Return on Assets -11%
  • Return on Equity -19%
  • Earnings Per Share -$0.37
  • Revenue Per Share $0
  • Quarterly Earnings Growth 0%
View More

Highlights

  • Market Capitalization 274.56 million
  • EBITDA -16656604
  • PEG Ratio -0.94
  • Analyst Target Price $17.63
  • Book Value Per Share $1.58
View More

Share Statistics

  • Shares Outstanding 48.77 million
  • Shares Float 40.37 million
  • % Held by Insiders 772%
  • % Held by Institutions 21.91%
  • Shares Short 2.31 million
  • Shares Short Prior Month 2.24 million
  • Short Ratio 14.27
  • Short % of Float 5%
  • Short % of Shares Outstanding 5%
View More

Technicals

  • Beta 1.56
  • 52 Week High $7.5
  • 52 Week Low $2.82
  • 50 Day Moving Average 6.05
  • 200 Day Moving Average 5.75
View More

Dividends

  • Dividend Date N/A
  • ExDividend Date N/A
  • Dividend Yield 0%
View More

MediciNova, Inc (MNOV) Dividend Calendar:

Ex-Dividend Date Payment Date Record Date Declared Date Amount

MediciNova, Inc (MNOV) Earnings History:

Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.


Quarter Date Report Date Actual Revenue Reported EPS EPS Estimate Deviation from Estimate
2020-12-312021-02-19$N/A-$0.06-$0.060%
2020-09-302020-10-26$N/A-$0.08-$0.1233.33%
2020-06-302020-07-28$N/A-$0.10-$0.100%
2020-03-312020-04-23$N/A-$0.06-$0.0825%
2019-12-312020-02-13$N/A-$0.05-$0.0837.5%
2019-09-302019-10-25$N/A-$0.05-$0.1566.67%
2019-06-302019-07-25$N/A-$0.09-$0.1225%
2019-03-312019-04-25$N/A-$0.11-$0.11-3.09%
2018-12-312019-02-13$N/A$-0.00-$0.0893.88%
2018-09-302018-10-25$N/A-$0.16-$0.11-45.45%
2018-06-302018-07-23$N/A-$0.08-$0.1123.81%
2018-03-312018-04-25$N/A-$0.12-$0.10-16.17%
2017-12-312018-02-13$N/A-$0.04-$0.0955.56%
2017-09-302017-10-23$N/A-$0.11-$0.09-29.41%
2017-06-302017-07-26$N/A-$0.08-$0.1015.79%
2017-03-312017-04-26$N/A-$0.09-$0.105.26%
2016-12-312017-02-14$N/A-$0.04-$0.0742.86%
2016-09-302016-10-25$N/A-$0.08-$0.05-60%
2016-06-302016-07-26$N/A-$0.10-$0.07-42.86%
2016-03-312016-04-27$N/A-$0.11-$0.08-46.67%
2015-12-312016-02-25$N/A-$0.09-$0.08-12.5%
2015-09-302015-10-30$N/A-$0.06-$0.1040%
2015-06-302015-07-30$N/A-$0.09-$0.08-12.5%
2015-03-312015-05-11$N/A-$0.09-$0.090%
2014-12-312015-03-12$N/A-$0.10-$0.09-11.11%
2014-09-302014-11-13$N/A-$0.10
2014-06-302014-08-15$N/A-$0.09
2014-03-312014-05-08$N/A-$0.10
2013-12-312014-03-28$6 million$0.14
2013-09-302013-11-08$2.36 million-$0.10
2013-06-302013-08-08$-2363807-$0.14-$0.11-27.27%
2013-03-312013-05-08$3000-$0.14-$0.13-7.69%
2012-12-312013-03-28$34000-$0.14-$0.140%
2012-09-302012-11-08$84000-$0.14-$0.1717.65%
2012-06-302012-08-09$494000-$0.14-$0.2646.15%
2012-03-312012-05-10$191000-$0.24-$0.2814.29%
2011-12-312012-03-29$N/A-$0.21-$0.2412.5%
2011-09-302011-11-15$N/A-$0.25-$0.2810.71%
2011-06-302011-08-16$N/A-$0.27-$0.3318.18%
2011-03-312011-05-17$N/A-$0.45-$0.35-28.57%
2010-12-312011-03-31$N/A-$0.40-$0.400%
2010-09-302010-11-15$N/A-$0.46-$0.44-4.55%
2010-06-302010-08-16$N/A-$0.35-$0.3910.26%
2010-03-312010-05-17$N/A-$0.42-$0.34-23.53%
2009-12-312010-03-24$N/A-$0.49-$0.43-13.95%
2009-09-302009-11-12$N/A-$0.40-$0.4613.04%
2009-06-302009-08-14$N/A-$0.39-$0.390%
2009-03-312009-05-15$N/A-$0.41-$0.26-57.69%
2008-12-312009-03-31$N/A-$0.12-$0.5076%
2008-09-302008-11-10$N/A-$0.40-$0.6639.39%
2008-06-302008-08-11$N/A-$0.40-$0.9758.76%
2008-03-312008-05-12$N/A-$0.89-$0.67-32.84%
2007-12-312008-03-17$N/A-$0.25-$0.9573.68%
2007-09-302007-11-09$N/A-$0.87-$0.903.33%
2007-06-302007-08-09$N/A-$1.68-$1.10-52.73%
2007-03-312007-05-10$N/A-$1.40
2006-12-312007-02-15$169000-$1.13-$0.61-85.25%

MediciNova, Inc (MNOV) Company Financial Statements:

Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.

Income Statement:
Date
Research Development
Income Before Tax
Selling General Administrative
Gross Profit
Ebit
Operating Income
Income Tax Expense
Total Revenue
Cost of Revenue
Total Other Income Expense Net
Net Income From Continuing Operations
Net Income Applicable to Common Shares
Cash Flow:
Date
Investments
Change to Liabilities
Total Cash Flow from Investing Activities
Net Borrowings
Total Cash Flow from Financial Activities
Change to Operating Activities
Change in Cash
Total Cash from Operating Activities
Depreciation
Other Cash Flow from Investing Activities
Change to Inventory
Change to Account Receivables
Other Cash Flow from Financing Activities
Change to Net Income
Capital Expenditures
Balance Sheet:
Date
Total Liabailities
Total Stockholder Equity
Other Current Liabilities
Total Assets
Common Stock
Other Current Assets
Retained Earnings
Other Liabilities
Other Assets
Cash
Total Current Liabilities
Other Stockholder Equity
Property, Plant & Equipment
Total Current Assets
Long Term Investments
Net Tangible Assets
Short Term Investments
Long Term Debt
Inventory
Accounts Payable

MediciNova, Inc (MNOV) Chart:

MediciNova, Inc (MNOV) News:

Below you will find a list of latest news for MediciNova, Inc (MNOV) from major news sources. You can filter the results to only show news from a specific source.

No recent news available

MediciNova, Inc (MNOV) Options:

A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.

Expiration Date Strike Last Price Type Volume Open Interest Implied Volatility In The Money Change Change Percent
2024-05-172.50CALL0 00FALSE00
2024-05-1750CALL0 00FALSE00
2024-05-177.50CALL0 00FALSE00
2024-05-172.50.4PUT0 0243.06TRUE00
2024-05-1750PUT0 0536.62TRUE00
2024-05-177.50PUT0 0281.35TRUE00
2024-07-192.50.25CALL0 49187.85FALSE00
2024-07-1950.08CALL0 200FALSE00
2024-07-197.50.05CALL0 10FALSE00
2024-07-192.51.25PUT0 90TRUE00
2024-07-1950PUT0 0173.85TRUE00
2024-07-197.50PUT0 0237.57TRUE00
2024-10-182.50.1CALL0 100FALSE00
2024-10-1850CALL0 00FALSE00
2024-10-187.50CALL0 00FALSE00
2024-10-182.51.11PUT0 1122.19TRUE00
2024-10-1850PUT0 0360.34TRUE00
2024-10-187.50PUT0 0395.79TRUE00
2030-12-1850.38PUT1 10TRUE-0.19-0.33

Latest MNOV Trades:

Date Shares Price
Jun 13, 2022 2:15 PM EST100$2.5
Jun 13, 2022 2:16 PM EST100$2.48

MediciNova, Inc (MNOV) SEC Filings:

An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.

Date Form Type Form Name Link
2020-06-243Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1226616/000168316820002054/0001683168-20-002054-index.htm
2017-11-06UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1226616/000000000017039209/0000000000-17-039209-index.htm
2019-08-14UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1226616/000000000019012453/0000000000-19-012453-index.htm
2018-01-09SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1226616/000021545718000083/0000215457-18-000083-index.htm
2019-02-08SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1226616/000021545719006657/0000215457-19-006657-index.htm
2020-02-05SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1226616/000083423720005940/0000834237-20-005940-index.htm
2017-09-22S-3Registration statement under Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1226616/000095012317008596/0000950123-17-008596-index.htm
2017-09-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1226616/000119312517279377/0001193125-17-279377-index.htm
2017-09-27CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1226616/000119312517296212/0001193125-17-296212-index.htm
2017-10-308-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1226616/000119312517323923/0001193125-17-323923-index.htm
2018-02-07424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1226616/000119312518034770/0001193125-18-034770-index.htm
2018-02-08424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1226616/000119312518036391/0001193125-18-036391-index.htm
2018-02-088-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1226616/000119312518036407/0001193125-18-036407-index.htm
2018-02-218-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1226616/000119312518052180/0001193125-18-052180-index.htm
2018-05-09DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1226616/000119312518157522/0001193125-18-157522-index.htm
2018-05-17SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1226616/000119312518165576/0001193125-18-165576-index.htm
2018-06-058-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1226616/000119312518183893/0001193125-18-183893-index.htm
2019-03-128-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1226616/000119312519072043/0001193125-19-072043-index.htm
2019-04-258-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1226616/000119312519119751/0001193125-19-119751-index.htm
2019-06-21S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1226616/000119312519178413/0001193125-19-178413-index.htm
2019-07-258-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1226616/000119312519202160/0001193125-19-202160-index.htm
2019-08-09S-3Registration statement under Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1226616/000119312519218079/0001193125-19-218079-index.htm
2019-08-20CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1226616/000119312519225366/0001193125-19-225366-index.htm
2019-08-23424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1226616/000119312519228004/0001193125-19-228004-index.htm
2019-08-238-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1226616/000119312519228009/0001193125-19-228009-index.htm
2019-10-288-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1226616/000119312519275403/0001193125-19-275403-index.htm
2020-10-218-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1226616/000119312520273282/0001193125-20-273282-index.htm
2017-07-2610-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1226616/000156459017014096/0001564590-17-014096-index.htm
2017-07-278-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1226616/000156459017014153/0001564590-17-014153-index.htm
2017-10-2310-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1226616/000156459017019774/0001564590-17-019774-index.htm
2017-10-248-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1226616/000156459017019800/0001564590-17-019800-index.htm
2017-11-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1226616/000156459017023421/0001564590-17-023421-index.htm
2018-02-1310-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1226616/000156459018001957/0001564590-18-001957-index.htm
2018-02-148-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1226616/000156459018002006/0001564590-18-002006-index.htm
2018-04-2510-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1226616/000156459018009050/0001564590-18-009050-index.htm
2018-04-268-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1226616/000156459018009151/0001564590-18-009151-index.htm
2018-04-26DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1226616/000156459018009345/0001564590-18-009345-index.htm
2018-04-26DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1226616/000156459018009354/0001564590-18-009354-index.htm
2018-06-118-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1226616/000156459018015417/0001564590-18-015417-index.htm
2018-07-2310-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1226616/000156459018017198/0001564590-18-017198-index.htm
2018-07-248-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1226616/000156459018017245/0001564590-18-017245-index.htm
2018-10-2510-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1226616/000156459018025127/0001564590-18-025127-index.htm
2018-10-268-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1226616/000156459018025198/0001564590-18-025198-index.htm
2019-02-1310-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1226616/000156459019002835/0001564590-19-002835-index.htm
2019-02-148-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1226616/000156459019002909/0001564590-19-002909-index.htm
2019-04-2510-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1226616/000156459019013055/0001564590-19-013055-index.htm
2019-04-268-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1226616/000156459019013191/0001564590-19-013191-index.htm
2019-04-26DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1226616/000156459019013386/0001564590-19-013386-index.htm
2019-05-01DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1226616/000156459019014897/0001564590-19-014897-index.htm
2019-06-118-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1226616/000156459019022269/0001564590-19-022269-index.htm
2019-07-2510-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1226616/000156459019026122/0001564590-19-026122-index.htm
2019-07-268-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1226616/000156459019026232/0001564590-19-026232-index.htm
2019-10-2410-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1226616/000156459019037792/0001564590-19-037792-index.htm
2019-10-258-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1226616/000156459019037824/0001564590-19-037824-index.htm
2020-02-1310-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1226616/000156459020004605/0001564590-20-004605-index.htm
2020-04-168-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1226616/000156459020016936/0001564590-20-016936-index.htm
2020-04-238-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1226616/000156459020018203/0001564590-20-018203-index.htm
2020-04-2310-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1226616/000156459020018206/0001564590-20-018206-index.htm
2020-04-27DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1226616/000156459020018822/0001564590-20-018822-index.htm
2020-04-28DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1226616/000156459020018919/0001564590-20-018919-index.htm
2020-06-178-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1226616/000156459020029646/0001564590-20-029646-index.htm
2020-06-228-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1226616/000156459020030005/0001564590-20-030005-index.htm
2020-07-2810-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1226616/000156459020033933/0001564590-20-033933-index.htm
2020-10-2610-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1226616/000156459020047628/0001564590-20-047628-index.htm
2017-08-234Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1226616/000168316817002204/0001683168-17-002204-index.htm
2017-11-064Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1226616/000168316817002840/0001683168-17-002840-index.htm
2017-11-133Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1226616/000168316817002950/0001683168-17-002950-index.htm
2017-11-134Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1226616/000168316817002952/0001683168-17-002952-index.htm
2017-12-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1226616/000168316817003308/0001683168-17-003308-index.htm
2018-01-054Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1226616/000168316818000059/0001683168-18-000059-index.htm
2018-01-094Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1226616/000168316818000087/0001683168-18-000087-index.htm
2018-01-094Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1226616/000168316818000089/0001683168-18-000089-index.htm
2018-01-094Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1226616/000168316818000090/0001683168-18-000090-index.htm
2018-01-094Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1226616/000168316818000091/0001683168-18-000091-index.htm
2018-03-074Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1226616/000168316818000614/0001683168-18-000614-index.htm
2018-06-053Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1226616/000168316818001591/0001683168-18-001591-index.htm
2018-06-084Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1226616/000168316818001634/0001683168-18-001634-index.htm
2018-06-084Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1226616/000168316818001635/0001683168-18-001635-index.htm
2018-06-084Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1226616/000168316818001636/0001683168-18-001636-index.htm
2019-01-074Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1226616/000168316819000025/0001683168-19-000025-index.htm
2019-01-114Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1226616/000168316819000079/0001683168-19-000079-index.htm
2019-01-174Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1226616/000168316819000147/0001683168-19-000147-index.htm
2019-01-174Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1226616/000168316819000148/0001683168-19-000148-index.htm
2019-01-174Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1226616/000168316819000149/0001683168-19-000149-index.htm
2019-01-174Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1226616/000168316819000150/0001683168-19-000150-index.htm
2019-03-044Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1226616/000168316819000530/0001683168-19-000530-index.htm
2019-05-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1226616/000168316819001515/0001683168-19-001515-index.htm
2019-06-114Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1226616/000168316819001853/0001683168-19-001853-index.htm
2019-06-114Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1226616/000168316819001854/0001683168-19-001854-index.htm
2019-06-114Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1226616/000168316819001855/0001683168-19-001855-index.htm
2019-06-134Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1226616/000168316819001890/0001683168-19-001890-index.htm
2020-01-104Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1226616/000168316820000087/0001683168-20-000087-index.htm
2020-01-104Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1226616/000168316820000088/0001683168-20-000088-index.htm
2020-01-104Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1226616/000168316820000089/0001683168-20-000089-index.htm
2020-03-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1226616/000168316820000786/0001683168-20-000786-index.htm
2020-03-134Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1226616/000168316820000807/0001683168-20-000807-index.htm
2020-03-164/AStatement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1226616/000168316820000840/0001683168-20-000840-index.htm
2020-04-134Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1226616/000168316820001157/0001683168-20-001157-index.htm
2020-04-134Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1226616/000168316820001158/0001683168-20-001158-index.htm
2020-06-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1226616/000168316820001952/0001683168-20-001952-index.htm
2020-06-174Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1226616/000168316820001984/0001683168-20-001984-index.htm
2020-06-174Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1226616/000168316820001986/0001683168-20-001986-index.htm
2020-06-243Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1226616/000168316820002054/0001683168-20-002054-index.htm
2020-08-074Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1226616/000168316820002584/0001683168-20-002584-index.htm
2020-09-164Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1226616/000168316820003158/0001683168-20-003158-index.htm
2020-10-223Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1226616/000168316820003512/0001683168-20-003512-index.htm
2020-10-224Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1226616/000168316820003513/0001683168-20-003513-index.htm
2017-10-02EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1226616/999999999517002532/9999999995-17-002532-index.htm
2019-08-22EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1226616/999999999519001951/9999999995-19-001951-index.htm

MediciNova, Inc (MNOV) Insider Transactions:

Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of MediciNova, Inc (MNOV). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 772%
Institutional Ownership: 2191%

Transaction Date Insider Name Insider Title Type Shares Number Shares Price Total Transaction Shares Held After Transaction Link
2019-05-13Hideki NagaoDirectorBuy1,000.002.772,770.001,000.00https://www.sec.gov/Archives/edgar/data/1226616/000168316819001515/0001683168-19-001515-index.htm
2017-08-21Yoshio IshizakaDirectorBuy5,000.005.1725,850.0010,000.00https://www.sec.gov/Archives/edgar/data/1226616/000168316817002204/0001683168-17-002204-index.htm
2019-02-28Masatsune OkajimaVP and Head of Japanese OfficeBuy105,000.007.00735,000.001,040,530.00https://www.sec.gov/Archives/edgar/data/1226616/000168316819000530/0001683168-19-000530-index.htm
2017-12-12Masatsune OkajimaVP and Head of Japanese OfficeBuy48,000.004.42212,160.00108,941.00https://www.sec.gov/Archives/edgar/data/1226616/000168316817003308/0001683168-17-003308-index.htm
2019-06-12Kazuko MatsudaChief Medical OfficerBuy37,000.004.80177,600.00109,457.00https://www.sec.gov/Archives/edgar/data/1226616/000168316819001890/0001683168-19-001890-index.htm
2020-03-13Kazuko MatsudaChief Medical OfficerBuy2,000.003.627,240.00111,476.00https://www.sec.gov/Archives/edgar/data/1226616/000168316820000807/0001683168-20-000807-index.htm
2020-04-08Kazuko MatsudaChief Medical OfficerBuy28,446.002.5472,252.84140,192.00https://www.sec.gov/Archives/edgar/data/1226616/000168316820001158/0001683168-20-001158-index.htm
2020-09-15Hideki NagaoDirectorSell1,000.005.785,780.0015,000.00https://www.sec.gov/Archives/edgar/data/1226616/000168316820003158/0001683168-20-003158-index.htm
2019-01-09Masatsune OkajimaVP and Head of Japanese OfficeBuy41,250.002.2090,750.00153,580.00https://www.sec.gov/Archives/edgar/data/1226616/000168316819000079/0001683168-19-000079-index.htm
2020-08-06Hideki NagaoDirectorBuy15,000.002.5838,700.0016,000.00https://www.sec.gov/Archives/edgar/data/1226616/000168316820002584/0001683168-20-002584-index.htm
2020-06-12Kazuko MatsudaChief Medical OfficerBuy20,000.005.13102,600.00160,192.00https://www.sec.gov/Archives/edgar/data/1226616/000168316820001952/0001683168-20-001952-index.htm
2019-02-28Masatsune OkajimaVP and Head of Japanese OfficeBuy35,700.007.34262,038.00189,280.00https://www.sec.gov/Archives/edgar/data/1226616/000168316819000530/0001683168-19-000530-index.htm
2019-02-28Masatsune OkajimaVP and Head of Japanese OfficeBuy85,000.002.54215,900.00274,280.00https://www.sec.gov/Archives/edgar/data/1226616/000168316819000530/0001683168-19-000530-index.htm
2019-02-28Masatsune OkajimaVP and Head of Japanese OfficeBuy63,750.002.46156,825.00338,030.00https://www.sec.gov/Archives/edgar/data/1226616/000168316819000530/0001683168-19-000530-index.htm
2019-02-28Masatsune OkajimaVP and Head of Japanese OfficeBuy80,000.004.10328,000.00418,030.00https://www.sec.gov/Archives/edgar/data/1226616/000168316819000530/0001683168-19-000530-index.htm
2019-02-28Masatsune OkajimaVP and Head of Japanese OfficeBuy42,500.004.10174,250.00460,530.00https://www.sec.gov/Archives/edgar/data/1226616/000168316819000530/0001683168-19-000530-index.htm
2019-02-28Masatsune OkajimaVP and Head of Japanese OfficeBuy105,000.002.64277,200.00565,530.00https://www.sec.gov/Archives/edgar/data/1226616/000168316819000530/0001683168-19-000530-index.htm
2019-02-28Masatsune OkajimaVP and Head of Japanese OfficeBuy15,000.003.2448,600.00580,530.00https://www.sec.gov/Archives/edgar/data/1226616/000168316819000530/0001683168-19-000530-index.htm
2017-11-02YUICHI IWAKIPresident and CEOBuy21,067.004.4293,116.14637,228.00https://www.sec.gov/Archives/edgar/data/1226616/000168316817002840/0001683168-17-002840-index.htm
2019-02-28Masatsune OkajimaVP and Head of Japanese OfficeBuy105,000.003.09324,450.00685,530.00https://www.sec.gov/Archives/edgar/data/1226616/000168316819000530/0001683168-19-000530-index.htm
2018-01-03YUICHI IWAKIPresident and CEOBuy53,363.004.42235,864.46690,591.00https://www.sec.gov/Archives/edgar/data/1226616/000168316818000059/0001683168-18-000059-index.htm
2019-02-28Masatsune OkajimaVP and Head of Japanese OfficeBuy30,000.003.91117,300.00715,530.00https://www.sec.gov/Archives/edgar/data/1226616/000168316819000530/0001683168-19-000530-index.htm
2018-03-05YUICHI IWAKIPresident and CEOBuy50,003.002.20110,006.60740,594.00https://www.sec.gov/Archives/edgar/data/1226616/000168316818000614/0001683168-18-000614-index.htm
2019-01-03YUICHI IWAKIPresident and CEOBuy18,572.002.2040,858.40759,392.00https://www.sec.gov/Archives/edgar/data/1226616/000168316819000025/0001683168-19-000025-index.htm
2020-03-12YUICHI IWAKIPresident and CEOBuy20,000.003.1062,000.00780,683.00https://www.sec.gov/Archives/edgar/data/1226616/000168316820000786/0001683168-20-000786-index.htm
2019-02-28Masatsune OkajimaVP and Head of Japanese OfficeBuy120,000.003.91469,200.00835,530.00https://www.sec.gov/Archives/edgar/data/1226616/000168316819000530/0001683168-19-000530-index.htm
2020-04-08YUICHI IWAKIPresident and CEOBuy60,417.002.54153,459.18841,100.00https://www.sec.gov/Archives/edgar/data/1226616/000168316820001157/0001683168-20-001157-index.htm
2019-02-28Masatsune OkajimaVP and Head of Japanese OfficeBuy100,000.006.10610,000.00935,530.00https://www.sec.gov/Archives/edgar/data/1226616/000168316819000530/0001683168-19-000530-index.htm